Gross Margin

With the hire of elite dealmaker George F. Schoen, the building materials giant is signaling a new era of aggressive M&A and strategic consolidation.

Moody's affirms the Estonian energy giant's Baa3 rating, but a negative outlook signals deep-seated risks from its oil shale legacy and market volatility.

Bio-Techne promotes Steve Crouse to lead its high-growth Diagnostics and Spatial Biology unit, signaling a strategic focus on innovation after a key divestiture.

A surge in healthcare job applications offers a prime opportunity, but new data reveals a critical bottleneck preventing companies from turning interest into hires.

From Millennial micro-cruises to Boomer bucket lists, a new report reveals the deep generational divides reshaping the future of travel and tourism.

Corporate apparel maker Unisync Corp. shifts from loss to profit, boosting margins and securing new deals, proving operational efficiency can trump lower sales.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.

A Dutch-German gas project powered by offshore wind achieves a top methane certification, offering a new blueprint for Europe's energy transition.

Pharma veteran Pinder Sahota joins digital health firm Reset Health, signaling a strategic shift to integrated care in the new era of weight-loss drugs.

A new report shows the carbon removal market has the tools to fight climate change, but widespread corporate inaction threatens to strand vital projects.

A new report reveals a 38% drop in ransomware, but the danger is evolving. Hackers now prefer silent, long-term intrusion over noisy encryption.

ARS Pharma's neffy challenges the EpiPen with new data on efficacy, cost-effectiveness, and patient preference, promising a less intimidating allergy emergency.

A new survey shows most family firms expect a leadership change soon, but few are prepared, creating a high-stakes gap between intent and action.

Investors eye Kontoor Brands' March 3rd report, seeking proof of sustained momentum for Wrangler and Helly Hansen amid a tough consumer market.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.

As Nordstrom marks 125 years, its year-long celebration is more than a party—it's a strategic move to bolster loyalty and adapt in a tough market.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

As it marks its 40th year, the legal finance giant's impressive 3.0x return on capital highlights the growing appeal of legal assets as a stable asset class.